Similar to the data from the ELISA-based assay, the immunoblotting assay confirmed the presence of serum anti-IFN-γ autoAbs in severe COVID-19 patients with positive autoAbs (P1 and P2), but not in COVID-19 patients with negative autoAbs (P3, P4, and P5) or in healthy control participants (H1) (Fig. 1e). This evidence concerns the gene IFNG and COVID-19.